81.10 -0.06 (-0.07%)
Before hours: 7:41AM EST
|Bid||81.01 x 1400|
|Ask||81.16 x 900|
|Day's range||80.96 - 82.30|
|52-week range||65.25 - 89.20|
|Beta (5Y monthly)||0.44|
|PE ratio (TTM)||17.93|
|Forward dividend & yield||2.60 (3.20%)|
|Ex-dividend date||14 Dec 2020|
|1y target est||N/A|
Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction
Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.